In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership changes continue at Sarepta Therapeutics and Rivus Pharmaceuticals, and Boehringer Ingelheim secures an exclusive license for a preclinical small-molecule program.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership changes continue at Sarepta Therapeutics and Rivus Pharmaceuticals, and Boehringer Ingelheim secures an exclusive license for a preclinical small-molecule program.
Alkermes has revealed its CEO succession plan after longtime chief executive Richard Pops announced his retirement. Pops has led the company for decades, overseeing its transition into a diversified neuroscience-focused biopharma. The leadership transition marks a pivotal moment as Alkermes continues advancing its commercial portfolio and pipeline strategy.
In broader leadership news, Sarepta Therapeutics’ CEO has announced plans to retire, while Rivus Pharmaceuticals has appointed a new chief executive to guide its next stage of growth. The moves reflect ongoing executive reshuffling across the biotech sector as companies adapt to shifting capital markets, regulatory dynamics, and pipeline priorities.
Finally, Boehringer Ingelheim has acquired an exclusive license to a preclinical small-molecule program from Sitryx Therapeutics. The agreement strengthens Boehringer’s research portfolio and underscores continued investment in early-stage assets through external innovation partnerships.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
